All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, March 3, 2021
Home » Topics » Gastrointestinal, BioWorld

Gastrointestinal, BioWorld
%{topic} RSS Feed RSS

Ascletis joins Madrigal and Viking in global race for THR-β agonist for NASH

Feb. 26, 2021
By Elise Mak
No Comments
Liver disease specialist Ascletis Pharma Inc. said its nonalcoholic steatohepatitis (NASH)-focused subsidiary, Gannex Pharma Co. Ltd., will start global development of its oral THR-β agonist, ASC-41, after it obtained an IND approval from the FDA based on positive phase I data generated in China.
Read More
Liver illustration
Bettering bile

New organoid marks progress to liver repair beyond hepatocytes

Feb. 18, 2021
By Nuala Moran
No Comments
Organoids grown from cholangiocytes – the epithelial cells of the bile duct – are poised to be used in ex vivo cell therapy to increase the number of donated livers that are suitable for transplant, and also for direct bile duct repairs.
Read More

Sagimet raises $80M crossover round to support FASN programs

Feb. 12, 2021
By Michael Fitzhugh
No Comments
Sagimet Biosciences Inc., a company developing an oral fatty acid synthase (FASN) inhibitor for the potential treatment of nonalcoholic steatohepatitis, has raised $80 million in a crossover financing led by an undisclosed public equity health care investment fund.
Read More
Stomach and intestine

GSK discontinues phase II trial of Immutep’s anti-LAG3 immunotherapy in ulcerative colitis

Jan. 22, 2021
By Tamra Sami
No Comments
PERTH, Australia – Sydney-based Immutep Ltd. announced that partner Glaxosmithkline plc is discontinuing a phase II ulcerative colitis trial of its anti-lymphocyte activation gene-3 (LAG-3) cell-depleting monoclonal antibody, derived from Immutep’s IMP-731 antibody that GSK licensed in 2010.
Read More
Doctor pointing at liver

Organ-on-a-chip bests standard toxicity tests

Jan. 21, 2021
By Nuala Moran
No Comments
In what is claimed as the first co-authored research between regulatory scientists at the U.S. FDA and a commercial manufacturer of organ-on-a-chip devices, CN Bio's Physiomimix system is shown to perform better than the current standard in vitro liver toxicity tests.
Read More

Terns closes $87M series C financing to advance NASH pipeline

Jan. 8, 2021
By David Ho
No Comments
HONG KONG - U.S. and China-based Terns Pharmaceuticals Inc. closed an $87 million series C financing round that will pave the way for the company’s pipeline of candidates to treat nonalcoholic steatohepatitis (NASH).
Read More

Sosei Heptares, GSK ink $481M deal tackling GPCR target for GI disorders

Dec. 21, 2020
By Nuala Moran
No Comments
LONDON – Sosei Heptares Ltd. has signed up Glaxosmithkline plc to take on the orphan G protein-coupled (GPCR) target GPR35, in a deal worth a potential $481 million.
Read More

Mirum lands backing for rare liver disease drug as field heats up

Dec. 9, 2020
By Michael Fitzhugh
No Comments
Fresh off hitting key regulatory milestones in Europe and the U.S. for its investigational cholestatic liver disease therapy, maralixibat, Mirum Pharmaceuticals Inc. has secured a $210 million deal with Oberland Capital Management LLC supporting the drug's potential commercialization and the company's pipeline development plans.
Read More
Macrophage illustration

Resolution raises $36M series A for macrophage cell therapy in liver cirrhosis

Dec. 2, 2020
By Nuala Moran
No Comments
LONDON – Syncona Ltd. has unveiled its fifth cell therapy startup, Resolution Therapeutics Ltd., which arrives on the scene with a £26.6 million (US$35.6 million) series A to exploit the ability of macrophages to stimulate liver repair.
Read More

Conference data for Nov. 16, 2020: AASLD

Nov. 16, 2020
No Comments
New and updated preclinical and clinical data presented by biopharma firms at The Liver Meeting of the American Association for the Study of Liver Diseases Nov. 13-16, including: Arbutus, Can-Fite, Dicerna, Gilead, Mallinckrodt, Mirum, Novo, Seal Rock, Theratechnologies, Twoxar
Read More
Previous 1 2 3 4 5 6 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 2.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 2.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing